Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review
Abstract
:1. Introduction
2. Current German Recommendations
- Despite Despite the transition from a pandemic level (defined as “the infection characterised by widespread international impact causing social disruption, economic loss, and general hardship”) to the endemic level (defined as “the outbreak with the consistent presence of the disease limited to a specific region, and predictable spread and rates”), the epidemiological situation of COVID-19 remains strongly distributed around the population.
- 2.
- The updated recommendations include the introduction of a new booster for specific population groups who received their last vaccination booster or had an infection 12 months ago or longer. The targeted groups are as follows:
- (1)
- Individuals aged ≥60 years;
- (2)
- Residents in nursing homes;
- (3)
- HCPs who have direct contact with patients and/or nursing home residents;
- (4)
- All individuals aged ≥6 months with underlying diseases, encompassing bedridden conditions, chronic obstructive lung disease (COPD), chronic cardiovascular, hepatic and renal diseases, diabetes mellitus and other metabolic diseases, obesity, chronic neurological diseases (e.g., dementia, stroke, mental retardation, psychological diseases), immunodeficiency (e.g., human immunodeficiency virus [HIV] infection, chronic inflammatory diseases under immunosuppressive therapy including post-organ transplantation), and active cancer;
- (5)
- Family members and individuals with direct contact with immunocompromised persons (e.g., after organ or stem cell transplantation, haemodialysis) aged ≥6 months.
- 3.
- The administration timing of the “yearly” booster is recommended during the autumn, aligning with statistical evidence indicating that disease waves tend to peak during the winter months. This strategic timing aims to maximise the effectiveness of the booster in preparation for the seasonal increase in COVID-19 cases. Additionally, it is suggested that, when indicated, the COVID-19 booster may be administered concurrently with the influenza or pneumococcal vaccine. This co-administration approach aims to optimise protection aims to optimise protection against both COVID-19 and influenza or pneumonia, particularly during periods of heightened respiratory pathogen activity, i.e., in the winter.
- 4.
- The choice of vaccine for the booster is recommended to be adapted to the prevalent viral variants in the region. The current variant in Germany is XBB.1.5 (as of 11.01.2024). In European Union (EU) countries, including Germany, the approved booster vaccines encompass various categories:
- -
- (monovalent) mRNA vaccines: Comirnaty Original and Comirnaty XBB.1.5 (BioNTech/Pfizer), Spikevax (Moderna; cautioned against use as a booster for individuals aged between 6 months and 5 years), and Spikevax XBB.1.5 (Moderna).
- -
- bivalent mRNA vaccines: Comirnaty Original/Omicron BA.4/5 and Comirnaty Original/Omicron BA.1 (BioNTech/Pfizer), Spikevax bivalent Original/Omicron BA.4/5 and Spikevax bivalent Original/Omicron BA.1 (Moderna). Notably, Moderna vaccines should be administered carefully to individuals aged < 30 years due to the risk of peri- and myocarditis.
- -
- viral vector vaccines: Vaxzevria (AstraZeneca) and JCOVDEN (Janssen Cilag International), recommended only for individuals aged ≥60 years due to the risk of thromboembolic events in younger individuals. Moreover, JCOVDEN must not be used as a booster in individuals who previously received mRNA or viral vector vaccines.
- -
- protein-based vaccines: Nuvaxovid (only for individuals aged ≥18 years) and Novaxovid XBB 1.5 (Novavax), seemingly suitable for young individuals due to the very low risk of peri- and myocarditis. However, there are limited scientific data on the use of these vaccines in pregnant and breastfeeding women.
- -
- inactivated whole-virus vaccine: COVID-19 vaccine Valneva (Valneva) is recommended only for individuals with contraindications to other vaccines and unsuitable for those who have already received Valneva or viral vector vaccines as part of their basic immunisation. Limited scientific data are available regarding the use of this vaccine in pregnant and breastfeeding women.
- 5.
- Pre-exposure prophylaxis (PEP) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is designed to complement vaccination and hygiene practices, not replace them. In specific cases, such as after stem cell transplantation (prior to immunological reconstitution), B-cell depletion therapies (when B-cell reconstitution is absent), CAR-T-cell therapies, severe immunosuppression (e.g., after solid organ transplantation or ongoing chemotherapy), and those with genetically-related immune defects leading to poor antiviral immunity, the use of Evusheld (AstraZeneca) may be considered. This agent comprises two monoclonal Ab, namely, tixagevimab and cilgavimab. However, it is crucial to note that the efficacy of this drug preparation is significantly reduced or non-existent against the currently circulating Omicron sublineages.
- 6.
- According to Section 22a of the German Infection Protection Law, foreign nationals residing in EU countries who have been vaccinated with vaccines not approved by the EU, such as Sinovac (Sinovac Biotech Ltd. SVA:NASDAQ GS, Beijing, China), Sinopharm (China National Pharmaceutical Group Co., Beijing, China), COVAXIN, (Bharat Biotech International Ltd., Turkapally, India), and Sputnik V (Russian Gamaleya Research Institute of Epidemiology and Microbiology), are required to repeat the EU-approved vaccination [2], even though some investigators found that the Sinopharm booster is safe and capable of rescuing immune signals and further strengthening the protective immune response by increasing nAb levels against some Omicron sublineages [7,9].
3. Recent Scientific Debates
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wei, D.; Yu, X.; Li, Y.; Chen, Y.; Chen, E.; Wang, Y.; Yang, Z.; Zhang, X. Sequential reinfection with Omicron variants elicits broader neutralizing antibody profiles in booster vaccinees and reduces the duration of viral shedding. J. Med. Virol. 2023, 95, e29151. [Google Scholar] [CrossRef] [PubMed]
- Robert Koch Institut, COVID-19-Impfempfehlung (Stand 11.01.2024). Available online: https://www.rki.de/SharedDocs/FAQ/COVID-Impfen/FAQ_Liste_STIKO_Empfehlungen.html#:~:text=Die%20STIKO%20empfiehlt%20f%C3%BCr%20Personen,im%20Alter%20%E2%89%A560%20Jahre (accessed on 31 January 2024).
- Jacobsen, H.; Sitaras, I.; Katzmarzyk, M.; Jiménez, V.C.; Naughton, R.; Higdon, M.M.; Knoll, M.D. Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2. NPJ Vaccines 2023, 8, 159. [Google Scholar] [CrossRef] [PubMed]
- Hornsby, H.; Nicols, A.R.; Longet, S.; Liu, C.; Tomic, A.; Angyal, A.; Kronsteiner, B.; Tyerman, J.K.; Tipton, T.; Zhang, P.; et al. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. Nat. Commun. 2023, 14, 5065. [Google Scholar] [CrossRef]
- Pérez-Alós, L.; Hansen, C.B.; Almagro Armenteros, J.J.; Madsen, J.R.; Heftdal, L.D.; Hasselbalch, R.B.; Pries-Heje, M.M.; Bayarri-Olmos, R.; Jarlhelt, I.; Hamm, S.R.; et al. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk. Nat. Commun. 2023, 14, 5624. [Google Scholar] [CrossRef]
- Munro, A.P.S.; Feng, S.; Janani, L.; Cornelius, V.; Aley, P.K.; Babbage, G.; Baxter, D.; Bula, M.; Cathie, K.; Chatterjee, K.; et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): A multicentre, blinded, phase 2, randomised trial. Lancet Infect. Dis. 2022, 22, 1131–1141. [Google Scholar] [CrossRef]
- Chenchula, S.; Chandra, M.B.; Adusumilli, M.B.; Ghanta, S.N.; Bommasani, A.; Kuttiappan, A.; Padmavathi, R.; Amerneni, K.C.; Chikatipalli, R.; Ghanta, M.K.; et al. Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: A systematic review. Rev. Med. Virol. 2024, 34, e2515. [Google Scholar] [CrossRef] [PubMed]
- Chalkias, S.; Harper, C.; Vrbicky, K.; Walsh, S.R.; Essink, B.; Brosz, A.; McGhee, A.; Tomassini, J.E.; Chen, X.; Chang, Y.; et al. A bivalent omicron-containing booster vaccine against COVID-19. N. Engl. J. Med. 2022, 387, 1279–1291. [Google Scholar] [CrossRef]
- Wang, J.; Deng, C.; Liu, M.; Liu, Y.; Li, L.; Huang, Z.; Shang, L.; Jiang, J.; Li, Y.; Mo, R.; et al. A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain. Nat. Commun. 2022, 13, 6866. [Google Scholar] [CrossRef]
- Song, S.; Madewell, Z.J.; Liu, M.; Longini, I.M.; Yang, Y. Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: A systematic review and meta-analysis of test-negative design studies. Front. Public Health 2023, 11, 1195908. [Google Scholar] [CrossRef]
- Li, L.; Xie, Z.; Li, Y.; Luo, M.; Zhang, L.; Feng, C.; Tang, G.; Huang, H.; Hou, R.; Xu, Y.; et al. Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants. Front. Cell Infect. Microbiol. 2023, 13, 1277880. [Google Scholar] [CrossRef]
- Reynolds, C.J.; Pade, C.; Gibbons, J.M.; Otter, A.D.; Lin, K.-M.; Sandoval, D.M.; Pieper, F.P.; Butler, D.K.; Liu, S.; Joy, G.; et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 2022, 377, eabq1841. [Google Scholar] [CrossRef] [PubMed]
- Gao, B.; He, L.; Bao, Y.; Chen, Y.; Lu, G.; Zhang, Y.; Xu, Y.; Su, B.; Xu, J.; Wang, Y.; et al. Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection. Cell Res. 2023, 33, 258–261. [Google Scholar] [CrossRef] [PubMed]
- Selva, K.J.; Ramanathan, P.; Haycroft, E.R.; Reynaldi, A.; Cromer, D.; Tan, C.W.; Wang, L.-F.; Wines, B.D.; Hogarth, P.M.; Downie, L.E.; et al. Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections. JCI Insight. 2023, 8, e172470. [Google Scholar] [CrossRef] [PubMed]
- Rubio-Casillas, A.; Redwan, E.M.; Uversky, V.N. Does SARS-CoV-2 induce IgG4 synthesis to evade the immune system? Biomolecules 2023, 13, 1338. [Google Scholar] [CrossRef] [PubMed]
- Lozano-Rodríguez, R.; Avendaño-Ortíz, J.; Terrón, V.; Montalbán-Hernández, K.; Casalvilla-Dueñas, J.; Bergón-Gutiérrez, M.; Mata-Martínez, P.; Martín-Quirós, A.; García-Garrido, M.; del Balzo-Castillo, Á.; et al. mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals. Front. Immunol. 2023, 14, 1136029. [Google Scholar] [CrossRef] [PubMed]
- Chevaisrakul, P.; Lumjiaktase, P.; Kietdumrongwong, P.; Chuatrisorn, I.; Chatsangjaroen, P.; Phanuphak, N. Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program. Sci. Rep. 2023, 13, 763. [Google Scholar] [CrossRef] [PubMed]
- Cai, C.; Gao, Y.; Adamo, S.; Rivera-Ballesteros, O.; Hansson, L.; Österborg, A.; Bergman, P.; Sandberg, J.K.; Ljunggren, H.-G.; Björkström, N.K.; et al. SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19. Sci. Immunol. 2023, 8, eadh0687. [Google Scholar] [CrossRef] [PubMed]
- Alahdal, M.; Elkord, E. Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities. Clin. Immunol. 2022, 245, 109177. [Google Scholar] [CrossRef]
- Vidarsson, G.; Dekkers, G.; Rispens, T. IgG subclasses and allotypes: From structure to effector functions. Front. Immunol. 2014, 5, 520. [Google Scholar] [CrossRef]
- Rahman, M.O.; Kamigaki, T.; Thandar, M.M.; Haruyama, R.; Yan, F.; Shibamura-Fujiogi, M.; Soe, J.K.M.; Islam, R.; Yoneoka, D.; Miyahara, R.; et al. Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: A systematic review and meta-analysis. BMJ Open 2023, 13, e076892. [Google Scholar] [CrossRef]
- Irrgang, P.; Gerling, J.; Kocher, K.; Lapuente, D.; Steininger, P.; Habenicht, K.; Wytopil, M.; Beileke, S.; Schäfer, S.; Zhong, J.; et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 2023, 8, eade2798. [Google Scholar] [CrossRef] [PubMed]
- Zhu, Q.; Xu, Y.; Wang, T.; Xie, F. Innate and adaptive immune response in SARS-CoV-2 infection—Current perspectives. Front. Immunol. 2022, 13, 1053437. [Google Scholar] [CrossRef] [PubMed]
- Boretti, A. mRNA vaccine boosters and impaired immune system response in immune compromised individuals: A narrative review. Clin. Exp. Med. 2024, 24, 23. [Google Scholar] [CrossRef] [PubMed]
- Bitounis, D.; Jacquinet, E.; Rogers, M.A.; Amiji, M.M. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug Discov. 2024, in press. [Google Scholar] [CrossRef]
- Kirsebom, F.C.M.; Harman, K.; Lunt, R.J.; Andrews, N.; Groves, N.; Aziz, N.A.; Hope, R.; Stowe, J.; Chand, M.; Ramsay, M.; et al. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England. Lancet Reg. Health Eur. 2023, 35, 100755. [Google Scholar] [CrossRef]
- Christophorou, E.; Nilsson, A.C.; Petersen, I.; Lindvig, S.O.; Davidsen, J.R.; Abazi, R.; Poulsen, M.K.; Pedersen, R.M.; Justesen, U.S.; Johansen, N.E.; et al. Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose. Front. Immunol. 2023, 14, 1270814. [Google Scholar] [CrossRef]
- Chenchula, S.; Amerneni, K.C.; Ghanta, M.K.; Padmavathi, R.; Chandra, M.B.; Adusumilli, M.B.; Chavan, M.; Mudda, S.; Gupta, R.; Lakhawat, B. Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review. Virology 2023, 584, 38–43. [Google Scholar] [CrossRef]
Basic Immunity | Hybrid Immunity |
---|---|
|
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pitak-Arnnop, P.; Ngamskulrungroj, P.; Mahanonda, N.; Auychai, P.; Frech, B.; Shavlokhova, V.; Stoll, C. Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review. Medicina 2024, 60, 385. https://doi.org/10.3390/medicina60030385
Pitak-Arnnop P, Ngamskulrungroj P, Mahanonda N, Auychai P, Frech B, Shavlokhova V, Stoll C. Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review. Medicina. 2024; 60(3):385. https://doi.org/10.3390/medicina60030385
Chicago/Turabian StylePitak-Arnnop, Poramate, Popchai Ngamskulrungroj, Nithi Mahanonda, Prim Auychai, Benjamin Frech, Veronika Shavlokhova, and Christian Stoll. 2024. "Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review" Medicina 60, no. 3: 385. https://doi.org/10.3390/medicina60030385